Type 1 Diabetes Research
Joslin researchers spearhead the fight to predict, prevent, detect, treat and eventually cure the insulin-dependent form of diabetes that often strikes the young.
Research at Joslin seeks to sort out the diabolically complicated details of the autoimmune attack and to work toward steps that can be taken to stop it.
Joslin researchers lead in pursuing several strategies to replenish the insulin-producing beta cells destroyed in the disease.
Thomas Serwold, Ph.D., who joined Joslin’s Immunobiology research section last year, talks about progress in understanding the attack that triggers type 1 diabetes.
An expert on adopting technology for managing type 1 diabetes, Howard Wolpert, M.D., answers questions about his lab’s Continuous Glucose Monitoring (CGM) studies and the quest for an artificial pancreas.
In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.
More on type 1 research
Page last updated: June 28, 2016